CpG Island Methylator Phenotype Associated with Tumor Recurrence in Tumor–Node–Metastasis Stage I Hepatocellular Carcinoma

Li, Binkui; Liu, Wenji; Wang, Li; Li, Meixiang; Wang, Jianping; Huang, Liang; Huang, Pinzhu; Yuan, Yunfei

doi:10.1245/s10434-010-0921-7

Cited by 41 publications

(24 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the meantime, the present study confirmed that the methylation frequency of ELF, RASSF1A, p16, and GSTP1, the average number of methylated genes or methylation frequencies with combination of at least two or three genes in HCC tissues were significantly higher than in nontumor, which is in consistence with previous reports (Lee et al, 2003;Yang et al, 2003;Wang et al, 2006;Li et al, 2010). All these results suggest that events of DNA methylation had taken place even early in the liver injury stages, and a trend of increase of methylated genes occurred during progression of HCC.…”

Section: Discussionsupporting

confidence: 92%

Analysis of DNA Methylation in Plasma for Monitoring Hepatocarcinogenesis

Huang

Yang

et al. 2015

Genetic Testing and Molecular Biomarkers

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 92%

Analysis of DNA Methylation in Plasma for Monitoring Hepatocarcinogenesis

Huang

Yang

et al. 2015

Genetic Testing and Molecular Biomarkers

View full text Add to dashboard Cite

show abstract

“…In accordance with our results, one previous study showed that HCC features a high frequency of CpG island hyper-methylation in the promoter regions; the aberrant hyper-methylation of GSTP1 tends to accelerate during the multistep process of hepatocarcinogenesis, and might be a possible means of predicting the development of HCC, especially in the premalignant stages (Lee et al, 2003). Similarly, Li et al (2010) concluded that CpG island methylation of GSTP1 may specifically define a subgroup of patients with unfavorable outcomes in TNM stage I HCC, suggesting that the examination of GSTP1 methylation may be useful for stratifying prognosis of patients with early-stage HCC and identifying patients who are at higher risk of recurrence.…”

Section: Discussionsupporting

confidence: 92%

“…According to the inclusion criteria, 14 cohort studies were included (Zhong et al, 2002;Lee et al, 2003;Tada et al, 2005;Wang et al, 2006;Zhang et al, 2006;Su et al, 2007;Harder et al, 2008;Chang et al, 2008;Moribe et al, 2009;Kiran et al, 2009;Li et al, 2010;Feng et al, 2010;Hua et al, 2011;Jain et al, 2012) and 89 articles were excluded. A total of 607 HCC samples in 14 cohort studies were included; additionally, 356 adjacent samples, 182 benign samples, and 133 normal samples were included.…”

Section: Baseline Characteristics Of Studies Includedmentioning

confidence: 99%

Correlation between promoter methylation in the GSTP1 gene and hepatocellular carcinoma development: a meta-analysis

Qf¹,

Qy²,

Ar³

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Epigenetic silencing of the GSTP1 gene by promoter methylation has been associated with increased risk and shortened survival in patients with hepatocellular carcinoma (HCC). We therefore conducted a meta-analysis to obtain a more precise estimate of this association. By searching the Cochrane Library, CBM, EMBASE, PubMed, and the Web of Science, we tabulated and analyzed parameters from each study. Results were summarized by meta-analyses using the version 12.0 STATA software. Odds ratios (ORs) and 95% confidence intervals (95%CIs) were also calculated in this analysis. A total of 14 cohort studies (tumor samples = 607, adjacent samples = 356, benign samples = 182, normal samples = 133) were included for the following statistical analysis. Our meta-analysis results demonstrated that the frequency of GSTP1 methylation in cancer tissues was significantly higher than those in adjacent tissues, benign tissues, and normal tissues (all P < 0.05). Further subgroup analysis by country indicated that the frequency of aberrant GSTP1 promoter methylation was correlated 6763 GSTP1 methylation and HCC ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 14 (2): 6762-6772 (2015) to the development of HCC among all the included experimental subgroups (all P < 0.05). The results indicate a significant association between GSTP1 methylation and poor outcomes in HCC patients.

show abstract

“…Promoter methylation of p15 and p16 resulting in unopposed cyclin D-CDK6 activation is a molecular mechanism conferring adverse prognosis in HCC. 82 A confirmation of the detrimental effect of p16 and p18 loss on patient prognosis comes from studies analyzing their immunohistochemical expression. 83,84 On the contrary, p16 gene sequence alterations do not seem to influence survival 85 and in an earlier study, methylation-specific PCR analysis of p16 inactivation did not correlate with prognosis.…”

Section: Cyclins Cyclin-dependent Kinases and Its Regulatorsmentioning

confidence: 99%

Tissue Biomarkers of Prognostic Significance in Hepatocellular Carcinoma

Pinato

Pirisi

Maslen

et al. 2014

Advances in Anatomic Pathology

View full text Add to dashboard Cite

Despite major advancements in the clinical management of hepatocellular carcinoma (HCC), the natural history of this disease is characterized by an invariably poor prognosis. However, there are significant interindividual variations in the biologic behavior of this tumor and this combined with the confounding effect of liver function on patient survival makes prognostic prediction particularly difficult. Several studies have attempted to investigate the prognostic role of tissue biomarkers to better understand the molecular basis of HCC progression. These studies have looked at several aspects of cancer biology including proliferative potential, invasive capacity, and angiogenic promotion utilizing different methodologies. The aim of this review is to summarize the role of tissue biomarkers in the prognostic prediction of HCC and to outline questions and strategies in the prognostic assessment of HCC.

show abstract

CpG Island Methylator Phenotype Associated with Tumor Recurrence in Tumor–Node–Metastasis Stage I Hepatocellular Carcinoma

Abstract: CIMP+ may specifically define a subgroup of patients with unfavorable outcome in TNM stage I HCC. Examination of CIMP status may be useful for stratifying prognosis of patients with early-stage HCC and identifying patients who are at higher risk for recurrence.

Cited by 41 publications

References 34 publications

Analysis of DNA Methylation in Plasma for Monitoring Hepatocarcinogenesis

Analysis of DNA Methylation in Plasma for Monitoring Hepatocarcinogenesis

Correlation between promoter methylation in the GSTP1 gene and hepatocellular carcinoma development: a meta-analysis

Tissue Biomarkers of Prognostic Significance in Hepatocellular Carcinoma

Contact Info

Product

Resources

About